• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

作者信息

Govindarajan Rangaswamy, Adusumilli Josna, Baxter Donna L, El-Khoueiry Anthony, Harik Sami I

出版信息

J Clin Oncol. 2006 Oct 1;24(28):e48. doi: 10.1200/JCO.2006.08.4608.

DOI:10.1200/JCO.2006.08.4608
PMID:17008686
Abstract
摘要

相似文献

1
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.RAF激酶抑制剂BAY 43 - 9006诱发的可逆性后部白质脑病综合征
J Clin Oncol. 2006 Oct 1;24(28):e48. doi: 10.1200/JCO.2006.08.4608.
2
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.索拉非尼诱导晚期肝细胞癌完全组织学缓解：一例报告
J Clin Oncol. 2011 Apr 20;29(12):e330-2. doi: 10.1200/JCO.2010.32.6785. Epub 2011 Jan 24.
3
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].索拉非尼（多吉美）用于肝细胞癌治疗：PRODIGE-AFEF建议
Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4.
4
Raf kinase inhibitors in oncology.肿瘤学中的Raf激酶抑制剂
Onkologie. 2005 Feb;28(2):101-7. doi: 10.1159/000083373.
5
[Clinical results of Nexavar for the treatment of kidney cancer].
Prog Urol. 2007 Feb;17(1 Suppl 1):150-3.
6
Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.瑞戈非尼治疗期间的可逆性后部白质脑病综合征：一例报告及与多激酶抑制剂相关的可逆性后部白质脑病综合征的文献综述
Clin Colorectal Cancer. 2014 Jun;13(2):127-30. doi: 10.1016/j.clcc.2013.12.003. Epub 2013 Dec 27.
7
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.索拉非尼的安全性、药代动力学及初步抗肿瘤活性：对四项晚期难治性实体瘤患者I期试验的综述
Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426.
8
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.棘状毛囊性角化过度疹：索拉非尼一种新的皮肤不良反应。
J Clin Oncol. 2010 Nov 1;28(31):e640-2. doi: 10.1200/JCO.2010.31.3783. Epub 2010 Sep 20.
9
Sorafenib-induced erythema multiforme.索拉非尼诱发的多形红斑。
J Am Acad Dermatol. 2007 Mar;56(3):527-8. doi: 10.1016/j.jaad.2006.10.981. Epub 2007 Jan 22.
10
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.索拉非尼阻断RAF/MEK/ERK通路，抑制肿瘤血管生成，并在肝癌模型PLC/PRF/5中诱导肿瘤细胞凋亡。
Cancer Res. 2006 Dec 15;66(24):11851-8. doi: 10.1158/0008-5472.CAN-06-1377.

引用本文的文献

1
Cancer Therapy-Induced Encephalitis.癌症治疗诱发的脑炎
Cancers (Basel). 2024 Oct 23;16(21):3571. doi: 10.3390/cancers16213571.
2
Neuro-ophthalmic complications of modern anti-cancer drugs.现代抗癌药物的神经眼科并发症。
Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2269-2281. doi: 10.1007/s00417-023-06350-4. Epub 2024 Feb 12.
3
Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review.安罗替尼治疗宫颈鳞状细胞癌相关的后部可逆性脑病综合征：病例报告及文献复习
Front Pharmacol. 2023 Dec 15;14:1255785. doi: 10.3389/fphar.2023.1255785. eCollection 2023.
4
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma.一名嗅神经母细胞瘤患者接受乐伐替尼治疗后出现后部可逆性脑病综合征
Brain Sci. 2022 Dec 23;13(1):33. doi: 10.3390/brainsci13010033.
5
Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients.抗血管内皮生长因子药物：在危重症 COVID-19 患者的治疗中作为有吸引力的靶点。
Int Immunopharmacol. 2021 Dec;101(Pt B):108257. doi: 10.1016/j.intimp.2021.108257. Epub 2021 Oct 16.
6
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.与乐伐替尼治疗甲状腺癌相关的后部可逆性脑病综合征和应激性心肌病：一例报告及文献复习
Oncotarget. 2018 Jun 15;9(46):28281-28289. doi: 10.18632/oncotarget.25606.
7
Neurological variability in chemotherapy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review.化疗诱导的后部可逆性脑病综合征合并血栓性微血管病的神经学变异性：病例报告及文献综述
Mol Clin Oncol. 2018 Jan;8(1):178-182. doi: 10.3892/mco.2017.1476. Epub 2017 Nov 2.
8
Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases.索拉非尼诱发肾细胞癌患者可逆性后部白质脑病：两例报告
Mol Clin Oncol. 2017 Aug;7(2):281-284. doi: 10.3892/mco.2017.1291. Epub 2017 Jun 13.
9
Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?抗血管生成酪氨酸激酶抑制剂与可逆性后部白质脑病综合征：低镁血症会是触发因素吗？
Drug Saf. 2017 May;40(5):373-386. doi: 10.1007/s40264-017-0508-3.
10
Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report.后部可逆性脑病综合征与抗血管生成药物：一例报告
Neuroophthalmology. 2011 Jan 16;35(1):32-37. doi: 10.3109/01658107.2010.539763. eCollection 2011.